CAPRICOR THERAPEUTICS, INC. Operating Lease, Payments
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Operating Lease, Payments of $614.67 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-14
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-06-30 was $614.67K, a 170.54% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-03-31 was $614.67K, a 170.54% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-12-31 was $247.47K, a 9.17% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-09-30 was $242.05K, a 9.48% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for fiscal 2025 was $943.92K, a 4.46% increase from fiscal 2024.
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $903.60K, a 12.64% increase from fiscal 2023.
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $802.22K.
- CAPRICOR THERAPEUTICS, INC. operating lease, payments for fiscal 2021 was $81.33K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $614.67K 10-Q · filed 2026-08-14 | $1.23M 10-Q · filed 2026-08-14 | $1.48M derived: sum of 3 quarters · filed 2026-08-14 | $1.72M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $614.67K 10-Q · filed 2026-05-13 | $862.14K derived: sum of 2 quarters · filed 2026-05-13 | $1.10M derived: sum of 3 quarters · filed 2026-05-13 | $1.33M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $247.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $489.52K derived: sum of 2 quarters · filed 2026-03-17 | $716.72K derived: sum of 3 quarters · filed 2026-08-14 | $943.92K 10-K · filed 2026-03-17 |
| 2025-09-30 | $242.05K 10-Q · filed 2025-11-10 | $469.25K derived: sum of 2 quarters · filed 2026-08-14 | $696.45K 10-Q · filed 2025-11-10 | $923.13K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $227.20K 10-Q · filed 2026-08-14 | $454.40K 10-Q · filed 2026-08-14 | $681.08K derived: sum of 3 quarters · filed 2026-08-14 | $902.18K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $227.20K 10-Q · filed 2026-05-13 | $453.88K derived: sum of 2 quarters · filed 2026-05-13 | $674.98K derived: sum of 3 quarters · filed 2026-05-13 | $904.17K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $226.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $447.78K derived: sum of 2 quarters · filed 2026-03-17 | $676.97K derived: sum of 3 quarters · filed 2026-03-17 | $903.60K 10-K · filed 2026-03-17 |
| 2024-09-30 | $221.10K 10-Q · filed 2025-11-10 | $450.30K derived: sum of 2 quarters · filed 2025-11-10 | $676.92K 10-Q · filed 2025-11-10 | $881.96K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $229.20K 10-Q · filed 2025-08-11 | $455.82K 10-Q · filed 2025-08-11 | $660.87K derived: sum of 3 quarters · filed 2025-08-11 | $859.92K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $226.63K 10-Q · filed 2025-05-14 | $431.67K derived: sum of 2 quarters · filed 2025-05-14 | $630.73K derived: sum of 3 quarters · filed 2025-05-14 | $829.78K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $205.04K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $404.10K derived: sum of 2 quarters · filed 2025-03-26 | $603.16K derived: sum of 3 quarters · filed 2025-03-26 | $802.22K 10-K · filed 2025-03-26 |
| 2023-09-30 | $199.06K 10-Q · filed 2024-11-14 | $398.12K derived: sum of 2 quarters · filed 2024-11-14 | $597.17K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $199.06K 10-Q · filed 2024-08-08 | $398.12K 10-Q · filed 2024-08-08 | ||
| 2021-12-31 | $81.33K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |